Store Performance Index shows overall performance of your app on app stores. It is based on combined ASO & reviews metrics.
The updated ASCVD Risk Estimator Plus uses up to date science and user feedback to help a clinician and patient build a customized risk lowering plan by estimating and monitoring change in 10-year ASCVD risk. Use the app to: • Estimate a patient’s initial 10-year ASCVD risk using the pooled cohort equation • Receive an individualized, risk-based, intervention approach • Project the impact of specific interventions on a patient’s risk • Guide clinician-patient discussion around customizing an intervention plan • Update risk at follow-up based on a patient’s response to therapy using the Million Hearts Longitudinal model Advice from the app is derived from the 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease, the 2018 ACC/AHA et.al Guideline on the Management of Blood Cholesterol, the 2017 ACC/AHA et.al Guideline on High Blood Pressure in Adults, the 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk, and the 2016 Million Hearts Longitudinal ASCVD Risk Assessment Tool user guide. The information and recommendations in this app are meant to support clinical decision making. They are not meant to represent the only or best course of care, or replace clinical judgment. Therapeutic options should be determined after discussion between the patient and their care provider.
User reviews affect conversion to installs and app rating. Featured and helpful reviews are the first to be noticed by users and in case of no response can affect download rate. This is why it is highly recommended to reply to them.
Developed by American College of Cardiology Foundation.
ASCVD Risk Estimator Plus is ranking in Medical
Last update was at Jul 21, 2021and the current version is 4.1.
ASCVD Risk Estimator Plus was downloaded 500000 times.
ASCVD Risk Estimator Plus was downloaded
To see all other keys and revenue click here org.acc.cvrisk
ASCVD Risk Estimator Plus have a 539a user reviews.